{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:13:52Z","timestamp":1781298832991,"version":"3.54.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81603055"],"award-info":[{"award-number":["No. 81603055"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13346-024-01680-0","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T17:06:04Z","timestamp":1722877564000},"page":"1342-1362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PBPK model of pegylated liposomal doxorubicin to simultaneously predict the concentration\u2013time profile of encapsulated and free doxorubicin in tissues"],"prefix":"10.1007","volume":"15","author":[{"given":"Xuewei","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1263-5540","authenticated-orcid":false,"given":"Le","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil(R)\u2013the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334.","journal-title":"J Control Release"},{"key":"1680_CR2","first-page":"1439","volume":"35","author":"N Sekiya","year":"2008","unstructured":"Sekiya N, Imamura A. [Doxil\u2013pegylated liposomal doxorubicin], Gan to kagaku ryoho. Cancer Chemother. 2008;35:1439\u201343.","journal-title":"Cancer Chemother"},{"key":"1680_CR3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419\u201336.","journal-title":"Clin Pharmacokinet"},{"key":"1680_CR4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2017.11.007","volume":"269","author":"LM Russell","year":"2018","unstructured":"Russell LM, Hultz M, Searson PC. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action. J Control Release. 2018;269:171\u20136.","journal-title":"J Control Release"},{"issue":"1","key":"1680_CR5","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","volume":"20","author":"M Mohamed","year":"2019","unstructured":"Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, Szebeni J, Ishida T. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20(1):710\u201324.","journal-title":"Sci Technol Adv Mater"},{"key":"1680_CR6","first-page":"1029","volume":"11","author":"T Safra","year":"2000","unstructured":"Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2, Annals of oncology\u202f: official journal of the European Society for. Med Oncol. 2000;11:1029\u201333.","journal-title":"Med Oncol"},{"key":"1680_CR7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","volume":"15","author":"XR Li","year":"2022","unstructured":"Li XR, Cheng XH, Zhang GN, Wang XX, Huang JM. Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. J Ovarian Res. 2022;15:96.","journal-title":"J Ovarian Res"},{"key":"1680_CR8","first-page":"162","volume":"10","author":"Z Lin","year":"2016","unstructured":"Lin Z, Monteiro-Riviere NA, Riviere JE. A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice. Nanotoxicology. 2016;10:162\u201372.","journal-title":"Nanotoxicology"},{"key":"1680_CR9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.addr.2011.05.017","volume":"63","author":"S Cai","year":"2011","unstructured":"Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev. 2011;63:901\u20138.","journal-title":"Adv Drug Deliv Rev"},{"key":"1680_CR10","doi-asserted-by":"crossref","first-page":"120358","DOI":"10.1016\/j.talanta.2019.120358","volume":"208","author":"H Wang","year":"2020","unstructured":"Wang H, Zheng M, Gao J, Wang J, Zhang Q, Fawcett JP, He Y, Gu J. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice. Talanta. 2020;208:120358.","journal-title":"Talanta"},{"key":"1680_CR11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/00003088-200342100-00002","volume":"42","author":"I Nestorov","year":"2003","unstructured":"Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet. 2003;42:883\u2013908.","journal-title":"Clin Pharmacokinet"},{"key":"1680_CR12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12272-020-01209-2","volume":"43","author":"JH Byun","year":"2020","unstructured":"Byun JH, Han D-G, Cho H-J, Yoon I-S, Jung IH. Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines. Arch Pharmacal Res. 2020;43:80\u201399.","journal-title":"Arch Pharmacal Res"},{"key":"1680_CR13","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/acsnano.9b08142","volume":"14","author":"YH Cheng","year":"2020","unstructured":"Cheng YH, He C, Riviere JE, Monteiro-Riviere NA, Lin Z. Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach. ACS Nano. 2020;14:3075\u201395.","journal-title":"ACS Nano"},{"key":"1680_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1208\/s12248-016-0010-3","volume":"19","author":"M Li","year":"2016","unstructured":"Li M, Zou P, Tyner K, Lee S. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles. AAPS J. 2016;19:26\u201342.","journal-title":"AAPS J"},{"key":"1680_CR15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.xphs.2018.10.037","volume":"108","author":"D Yuan","year":"2019","unstructured":"Yuan D, He H, Wu Y, Fan J, Cao Y. Physiologically Based Pharmacokinetic Modeling of Nanoparticles. J Pharm Sci. 2019;108:58\u201372.","journal-title":"J Pharm Sci"},{"key":"1680_CR16","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1021\/nn1018818","volume":"4","author":"M Li","year":"2010","unstructured":"Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano. 2010;4:6303\u201317.","journal-title":"ACS Nano"},{"issue":"7","key":"1680_CR17","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/nano10071267","volume":"10","author":"W Utembe","year":"2020","unstructured":"Utembe W, Clewell H, Sanabria N, Doganis P, Gulumian M. Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials. Nanomaterials. 2020;10(7):1267.","journal-title":"Nanomaterials."},{"key":"1680_CR18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yrtph.2015.06.019","volume":"73","author":"LM Sweeney","year":"2015","unstructured":"Sweeney LM, MacCalman L, Haber LT, Kuempel ED, Tran CL. Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats. Regul Toxicol Pharmacol. 2015;73:151\u201363.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"1680_CR19","doi-asserted-by":"crossref","first-page":"012028","DOI":"10.1088\/1742-6596\/151\/1\/012028","volume":"151","author":"L MacCalman","year":"2009","unstructured":"MacCalman L, CL T, Kuempel E. Development of a bio-mathematical model in rats to describe clearance, retention and translocation of inhaled nano particles throughout the body. J Physics Conf Ser. 2009;151(1):012028.","journal-title":"J Physics Conf Ser"},{"key":"1680_CR20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1021\/acs.nanolett.5b03854","volume":"16","author":"X Liang","year":"2016","unstructured":"Liang X, Wang H, Grice JE, Li L, Liu X, Xu ZP, Roberts MS. Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles. Nano Lett. 2016;16:939\u201345.","journal-title":"Nano Lett"},{"key":"1680_CR21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jconrel.2022.03.007","volume":"345","author":"J Chen","year":"2022","unstructured":"Chen J, Yuan M, Madison CA, Eitan S, Wang Y. Blood-brain barrier crossing using magnetic stimulated nanoparticles. J Control Release. 2022;345:557\u201371.","journal-title":"J Control Release"},{"key":"1680_CR22","doi-asserted-by":"crossref","unstructured":"Henrique Silva A, Lima Jr E, Vasquez Mansilla M, Zysler RD, Mojica Pisciotti ML, Locatelli C, Kumar Reddy Rajoli R, Owen A, Creczynski-Pasa TB, Siccardi M. A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. European J Nanomed. 2017;9(2):79-90.","DOI":"10.1515\/ejnm-2017-0001"},{"issue":"4","key":"1680_CR23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/pharmaceutics11040179","volume":"11","author":"M Aborig","year":"2019","unstructured":"Aborig M, Malik PR, Nambiar S, Chelle P, Darko J, Mutsaers A, Edginton AN, Fleck A, Osei E, Wettig S. Biodistribution and Physiologically-Based Pharmacokinetic Modeling of Gold Nanoparticles in Mice with Interspecies Extrapolation. Pharmaceutics. 2019;11(4):179.","journal-title":"Pharmaceutics"},{"key":"1680_CR24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.csbj.2020.02.014","volume":"18","author":"P Dogra","year":"2020","unstructured":"Dogra P, Butner JD, Ram\u00edrez JR, Chuang YL, Noureddine A, Brinker CJ, Cristini V, Wang Z. A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery. Comput Struct Biotechnol J. 2020;18:518\u201331.","journal-title":"Comput Struct Biotechnol J"},{"key":"1680_CR25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0168-3659(99)00110-8","volume":"61","author":"H Harashima","year":"1999","unstructured":"Harashima H, Iida S, Urakami Y, Tsuchihashi M, Kiwada H. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic\/pharmacodynamic modeling. J Control Release. 1999;61:93\u2013106.","journal-title":"J Control Release"},{"key":"1680_CR26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0169-409X(99)00039-3","volume":"40","author":"H Harashima","year":"1999","unstructured":"Harashima H, Tsuchihashi M, Iida S, Doi H, Kiwada H. Pharmacokinetic\/pharmacodynamic modeling of antitumor agents encapsulated into liposomes. Adv Drug Deliv Rev. 1999;40:39\u201361.","journal-title":"Adv Drug Deliv Rev"},{"key":"1680_CR27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp900122j","volume":"7","author":"S Qin","year":"2010","unstructured":"Qin S, Seo JW, Zhang H, Qi J, Curry FR, Ferrara KW. An imaging-driven model for liposomal stability and circulation. Mol Pharm. 2010;7:12\u201321.","journal-title":"Mol Pharm"},{"key":"1680_CR28","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1038\/psp.2012.16","volume":"1","author":"BS Hendriks","year":"2012","unstructured":"Hendriks BS, Reynolds JG, Klinz SG, Geretti E, Lee H, Leonard SC, Gaddy DF, Espelin CW, Nielsen UB, Wickham TJ. Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors. CPT Pharmacometrics Syst Pharmacol. 2012;1:e15.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1680_CR29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2018.06.002","volume":"284","author":"MD McSweeney","year":"2018","unstructured":"McSweeney MD, Wessler T, Price LSL, Ciociola EC, Herity LB, Piscitelli JA, Zamboni WC, Forest MG, Cao Y, Lai SK. A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse. J Control Release. 2018;284:171\u20138.","journal-title":"J Control Release"},{"key":"1680_CR30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2019.06.029","volume":"308","author":"L Jablonka","year":"2019","unstructured":"Jablonka L, Ashtikar M, Gao G, Jung F, Thurn M, Preuss A, Scheglmann D, Albrecht V, Roder B, Wacker MG. Advanced in silico modeling explains pharmacokinetics and biodistribution of temoporfin nanocrystals in humans. J Control Release. 2019;308:57\u201370.","journal-title":"J Control Release"},{"key":"1680_CR31","doi-asserted-by":"crossref","first-page":"122250","DOI":"10.1016\/j.ijpharm.2022.122250","volume":"627","author":"T Matsumoto","year":"2022","unstructured":"Matsumoto T, Masuo Y, Tanaka A, Kimura T, Ioroi T, Yamakawa T, Kitahara H, Kato Y. A physiologically based pharmacokinetic and pharmacodynamic model for disposition of FF-10832. Int J Pharm. 2022;627:122250.","journal-title":"Int J Pharm"},{"key":"1680_CR32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11095-013-1127-z","volume":"31","author":"L Kagan","year":"2014","unstructured":"Kagan L, Gershkovich P, Wasan KM, Mager DE. Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition. Pharm Res. 2014;31:35\u201345.","journal-title":"Pharm Res"},{"key":"1680_CR33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3109\/00498254.2016.1155128","volume":"46","author":"XF Lu","year":"2016","unstructured":"Lu XF, Bi K, Chen X. Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes. Xenobiotica. 2016;46:1093\u2013104.","journal-title":"Xenobiotica"},{"key":"1680_CR34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11538-021-00950-z","volume":"83","author":"AM Talkington","year":"2021","unstructured":"Talkington AM, Wessler T, Lai SK, Cao Y, Forest MG. Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery. Bull Math Biol. 2021;83:123.","journal-title":"Bull Math Biol"},{"key":"1680_CR35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jconrel.2022.01.022","volume":"343","author":"AM Talkington","year":"2022","unstructured":"Talkington AM, McSweeney MD, Wessler T, Rath MK, Li Z, Zhang T, Yuan H, Frank JE, Forest MG, Cao Y, Lai SK. A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes. J Control Release. 2022;343:518\u201327.","journal-title":"J Control Release"},{"key":"1680_CR36","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1002\/jps.22115","volume":"99","author":"BA Howell","year":"2010","unstructured":"Howell BA, Chauhan A. A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. J Pharm Sci. 2010;99:3601\u201319.","journal-title":"J Pharm Sci"},{"key":"1680_CR37","first-page":"2178","volume":"12","author":"MC Montanha","year":"2022","unstructured":"Montanha MC, Howarth A, Mohamed DA, Loier E, Main L, Rosslein M, Delmaar C, Prina-Mello A, Siccardi M. A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human, Drug Deliv. Transl Res. 2022;12:2178\u201386.","journal-title":"Transl Res"},{"key":"1680_CR38","first-page":"1345","volume":"7","author":"M Li","year":"2012","unstructured":"Li M, Panagi Z, Avgoustakis K, Reineke J. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content. Int J Nanomedicine. 2012;7:1345\u201356.","journal-title":"Int J Nanomedicine"},{"key":"1680_CR39","first-page":"9","volume":"19","author":"J Methaneethorn","year":"2023","unstructured":"Methaneethorn J, Tengcharoen K, Leelakanok N, AlEjielat R. Population pharmacokinetics of doxorubicin: A systematic review, Asia Pac. J Clin Oncol. 2023;19:9\u201326.","journal-title":"J Clin Oncol"},{"key":"1680_CR40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bdd.2229","volume":"41","author":"JB Lee","year":"2020","unstructured":"Lee JB, Zhou S, Chiang M, Zang X, Kim TH, Kagan L. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling. Biopharm Drug Dispos. 2020;41:192\u2013205.","journal-title":"Biopharm Drug Dispos"},{"key":"1680_CR41","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/jat.2550030607","volume":"3","author":"WT Stott","year":"1983","unstructured":"Stott WT, Dryzga MD, Ramsey JC. Blood-flow distribution in the mouse. J Appl Toxicol. 1983;3:310\u20132.","journal-title":"J Appl Toxicol"},{"key":"1680_CR42","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093\u20135.","journal-title":"Pharm Res"},{"key":"1680_CR43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","volume":"13","author":"RP Brown","year":"1997","unstructured":"Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13:407\u201384.","journal-title":"Toxicol Ind Health"},{"key":"1680_CR44","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1021\/acs.molpharmaceut.6b00974","volume":"14","author":"IR Dubbelboer","year":"2017","unstructured":"Dubbelboer IR, Lilienberg E, Sjogren E, Lennernas H. A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition. Mol Pharm. 2017;14:686\u201398.","journal-title":"Mol Pharm"},{"key":"1680_CR45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39:67\u201386.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1680_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.01.002","volume":"519","author":"R Luo","year":"2017","unstructured":"Luo R, Li Y, He M, Zhang H, Yuan H, Johnson M, Palmisano M, Zhou S, Sun D. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. Int J Pharm. 2017;519:1\u201310.","journal-title":"Int J Pharm"},{"key":"1680_CR47","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jps.10161","volume":"91","author":"DL Gustafson","year":"2002","unstructured":"Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci. 2002;91:1488\u2013501.","journal-title":"J Pharm Sci"},{"key":"1680_CR48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00434396","volume":"5","author":"PB Johansen","year":"1981","unstructured":"Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol. 1981;5:267\u201370.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1680_CR49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1049\/nbt2.12111","volume":"17","author":"A Mehrabian","year":"2023","unstructured":"Mehrabian A, Dadpour S, Mashreghi M, Zarqi J, Askarizadeh A, Badiee A, Arabi L, Moosavian SA, Jaafari MR. The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre-insertion and post-insertion methods for brain delivery in normal mice. IET Nanobiotechnol. 2023;17:112\u201324.","journal-title":"IET Nanobiotechnol"},{"key":"1680_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11671-020-03334-9","volume":"15","author":"M Mashreghi","year":"2020","unstructured":"Mashreghi M, Zamani P, Moosavian SA, Jaafari MR. Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma. Nanoscale Res Lett. 2020;15:1\u20133.","journal-title":"Nanoscale Res Lett"},{"key":"1680_CR51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/jpp\/rgaa005","volume":"73","author":"SM Gheibihayat","year":"2021","unstructured":"Gheibihayat SM, Jaafari MR, Hatamipour M, Sahebkar A. Improvement of the pharmacokinetic characteristics of liposomal doxorubicin using CD47 biomimickry. J Pharm Pharmacol. 2021;73:169\u201377.","journal-title":"J Pharm Pharmacol"},{"key":"1680_CR52","doi-asserted-by":"crossref","first-page":"692741","DOI":"10.3389\/fphar.2021.692741","volume":"12","author":"Z Tan","year":"2021","unstructured":"Tan Z, Zhang Y, Wang C, Sun L. Physiologically based pharmacokinetic modeling of cefadroxil in mouse, rat, and human to predict concentration\u2013time profile at infected tissue. Front Pharmacol. 2021;12:692741.","journal-title":"Front Pharmacol"},{"key":"1680_CR53","doi-asserted-by":"crossref","first-page":"114765","DOI":"10.1016\/j.taap.2019.114765","volume":"384","author":"L Deng","year":"2019","unstructured":"Deng L, Liu H, Ma Y, Miao Y, Fu X, Deng Q. Endocytosis mechanism in physiologically-based pharmacokinetic modeling of nanoparticles. Toxicol Appl Pharmacol. 2019;384:114765.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1680_CR54","first-page":"560","volume":"123","author":"L Sun","year":"2018","unstructured":"Sun L, Wang C, Zhang Y. A physiologically based pharmacokinetic model for valacyclovir established based on absolute expression quantity of hPEPT1 and its application, European journal of pharmaceutical sciences\u202f: official journal of the European Federation for. Pharm Sci. 2018;123:560\u20138.","journal-title":"Pharm Sci"},{"issue":"1","key":"1680_CR55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0022-1759(96)00045-2","volume":"193","author":"TL Ten Hagen","year":"1996","unstructured":"Ten Hagen TL, Van Vianen W, Bakker-Woudenberg IA. Isolation and characterization of murine Kupffer cells and splenic macrophages. J Immunol Methods. 1996;193(1):81\u201391.","journal-title":"J Immunol Methods"},{"key":"1680_CR56","first-page":"3365","volume":"8","author":"G Bachler","year":"2013","unstructured":"Bachler G, von Goetz N, Hungerbuhler K. A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles. Int J Nanomedicine. 2013;8:3365\u201382.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"1680_CR57","first-page":"139","volume":"54","author":"PG Holt","year":"1985","unstructured":"Holt PG, Degebrodt A, Venaille T, O\u2019leary C, Krska K, Flexman J, Farrell H, Shellam G, Young P, Penhale J, Robertson T. Preparation of interstitial lung cells by enzymatic digestion of tissue slices: preliminary characterization by morphology and performance in functional assays. Immunology. 1985;54(1):139.","journal-title":"Immunology"},{"key":"1680_CR58","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jconrel.2005.03.030","volume":"107","author":"XB Xiong","year":"2005","unstructured":"Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release. 2005;107:262\u201375.","journal-title":"J Control Release"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01680-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01680-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01680-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:13:38Z","timestamp":1740766418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01680-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01680-0","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"20 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval is required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed with publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}